This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Young, W. Articles by DeCrescito, V. Search for Related Content PubMed PubMed Citation Articles by Young, W. Articles by DeCrescito, V.

Stroke, Vol 19, 1013-1019, Copyright © 1988 by American Heart Association

ARTICLES

21-Aminosteroid reduces ion shifts and edema in the rat middle cerebral artery occlusion model of regional ischemia

W Young, JC Wojak and V DeCrescito
Department of Neurosurgery, New York University Medical Center, New York.

U74006F is a member of a new family of steroid drugs called 21- aminosteroids, which are potent inhibitors of lipid peroxidation with little or no glucocorticoid or mineralocorticoid activity. We investigated the effects of U74006F on the early ionic edema produced by middle cerebral artery occlusion in rats. Intravenous doses of 3 mg/kg U74006F were given 10 minutes and 3 hours after occlusion. Tissue concentrations of Na+, K+, and water at and around the infarct site were measured by atomic absorption spectroscopy and by wet-dry weight measurements 24 hours after occlusion. Compared with vehicle treatment, U74006F treatment reduced brain water entry, Na+ accumulation, K+ loss, and net ion shift by 25-50% in most brain areas sampled in the frontal and parietal cortex. However, reductions of ionic edema were most prominent and reached significance (p less than 0.005, unpaired two- tailed t test) mostly in the frontoparietal and parietal cortex areas adjacent to the infarct site. Our findings suggest that a steroid drug without glucocorticoid or mineralocorticoid activity can reduce edema in cerebral ischemia but that the effects are largely limited to tissues in which collateral blood flow may be present.

This article has been cited by other articles:

				N. Sakellaridis and D. Panagopoulos Significance of Experimental Infarct Size as an Indicator of Therapeutic Efficacy in Humans Stroke, September 1, 2007; 38(9): e89 - e90. [Full Text] [PDF]

				Y. Numagami and S. T. Ohnishi S-Allylcysteine Inhibits Free Radical Production, Lipid Peroxidation and Neuronal Damage in Rat Brain Ischemia J. Nutr., March 1, 2001; 131(3): 1100S - 1105. [Abstract] [Full Text]

				R. J. Kavanagh and P. C. A. Kam Lazaroids: efficacy and mechanism of action of the 21-aminosteroids in neuroprotection Br. J. Anaesth., January 1, 2001; 86(1): 110 - 119. [Abstract] [Full Text] [PDF]

				Tirilazad Mesylate in Acute Ischemic Stroke : A Systematic Review Stroke, September 1, 2000; 31(9): 2257 - 2265. [Abstract] [Full Text] [PDF]

				R. F. Villa and A. Gorini Pharmacology of Lazaroids and Brain Energy Metabolism: A Review Pharmacol. Rev., March 1, 1997; 49(1): 99 - 136. [Abstract] [Full Text] [PDF]

				A Randomized Trial of Tirilazad Mesylate in Patients With Acute Stroke (RANTTAS) Stroke, September 1, 1996; 27(9): 1453 - 1458. [Abstract] [Full Text]

				T. B. Muller, O. Haraldseth, R. A. Jones, G. Sebastiani, C. F. Lindboe, G. Unsgard, and A. N. Oksendal Perfusion and Diffusion-Weighted MR Imaging for In Vivo Evaluation of Treatment With U74389G in a Rat Stroke Model Stroke, August 1, 1995; 26(8): 1453 - 1458. [Abstract] [Full Text]

				V. S. Miller Topical Review Article: Pharmacologic Management of Neonatal Cerebral Ischemia and Hemorrhage: Old and New Directions J Child Neurol, January 1, 1993; 8(1): 7 - 18. [Abstract] [PDF]